Levothyroxine enhances glucose clearance and blunts the onset of experimental type 1 diabetes mellitus in mice

Abstract

Thyroid hormones induce several changes in whole body metabolism that are known to improve metabolic homeostasis. However, adverse side effects have prevented its use in the clinic. In view of the promising effects of thyroid hormones, we investigated the effects of levothyroxine supplementation on glucose homeostasis. EXPERIMENTAL APPROACHC57BL/6 mice were treated with levothyroxine from birth to 24 weeks of age, when mice were killed. The effects of levothyroxine supplementation on metabolic health were determined. C57BL/6 mice treated with levothyroxine for 2 weeks and then challenged with streptozotocin to monitor survival. Mechanistic experiments were conducted in the pancreas, liver and skeletal muscle. RIP-B7.1 mice were treated with levothyroxine for 2 weeks and were subsequently immunized to trigger experimental autoimmune diabetes (EAD). Metabolic tests were performed. Mice were killed and metabolic tissues were extracted for immunohistological analyses. KEY RESULTSLong-term levothyroxine supplementation enhanced glucose clearance and reduced circulating glucose in C57BL/6 mice. Levothyroxine increased simultaneously the proliferation and apoptosis of pancreatic beta cells, promoting the maintenance of a highly insulin-expressing beta cell population. Levothyroxine increased circulating insulin levels, inducing sustained activation of IRS1-AKT signalling in insulin-target tissues. Levothyroxine-treated C57BL/6 mice challenged with streptozotocin exhibited extended survival. Levothyroxine blunted the onset of EAD in RIP-B7.1 mice by inducing beta cell proliferation and preservation of insulin-expressing cells. CONCLUSIONS AND IMPLICATIONSInterventions based on the use of thyroid hormones or thyromimetics could be explored to provide therapeutic benefit in patients with type 1 diabetes mellitus.

LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus

“…Islet viability was assessed using the MTT assay, according to the manufacturer’s recommendations (Roche, Spain). In some instance, protein extracts were prepared from T2DM islets and cleaved-caspase-3 activity was assessed by western blot analysis 57 .…”

The type 2 diabetes-associated HMG20A gene is mandatory for islet beta cell functional maturity

“…Circulating glucose levels were measured from tail vein blood samples using an Optium Xceed glucometer (Abbott Scientifica SA, Barcelona, Spain). Insulin tolerance tests (ITT) and glucose tolerance test (OGTT) were performed as previously described 38 . At 15 weeks, mice were sacrificed by cervical dislocation and pancreas extracted for histological processing.…”

Molecular Modelling of Islet β-Cell Adaptation to Inflammation in Pregnancy and Gestational Diabetes Mellitus

“…In this regard, women with subclinical hypothyroidism are at a significantly greater risk of developing GDM [16] while decreased levels of free thyroxin (FT4) during early pregnancy have been correlated with an increased incidence of GDM [17,18]. Interestingly, T4 supplementation has been shown to increase circulating insulin levels as well as glucose clearance in mice and to delay hyperglycemia in a mouse model of autoimmune diabetes, correlating with an increase in β-cell proliferation [19].…”